Modified renal function in pregnancy: Impact on emtricitabine pharmacokinetics

British Journal of Clinical Pharmacology

Volumn 78, Issue 6, 2014, Pages 1378-1386

  Valade, Elodie ^a,b,c   Tréluyer, Jean Marc ^a,b,c,d,e   Dabis, François ^f   Arrivé, Elise ^f   Pannier, Emmanuelle ^c,e   Benaboud, Sihem ^b,c,d,e   Fauchet, Floris ^a,b,c   Bouazza, Naim ^b,c,d   Foissac, Frantz ^b,c,d   Urien, Saik ^a,b,c,d   Hirt, Déborah ^a,b,c,e  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c DHU Risques et Grossesse   (France)

^d INSERM   (France)

^e Institut Cochin   (France)

^f UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

emtricitabine; Population pharmacokinetics; Pregnancy

Indexed keywords

EMTRICITABINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; CREATININE; DEOXYCYTIDINE;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DELIVERY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG MONITORING; FEMALE; FIRST TRIMESTER PREGNANCY; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC50; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; PERINATAL DRUG EXPOSURE; PREGNANCY; PREGNANT WOMAN; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY; ANALOGS AND DERIVATIVES; BIOLOGICAL MODEL; BLOOD; METABOLISM;

AREA UNDER CURVE; CREATININE; DEOXYCYTIDINE; EMTRICITABINE; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; MODELS, BIOLOGICAL; PREGNANCY;

EID: 84918837557     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12457     Document Type: Article

References (27)

1. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents. Recommendations for a public health approach, 2010 revision. 2010. Available at http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf (last accessed 4 April 2014).
2. Blum MR, Chittick GE, Begley JA, Zong J. Steady-state pharmacokinetics of emtricitabine and tenofovir disoproxil fumarate administered alone and in combination in healthy volunteers. J Clin Pharmacol 2007; 47: 751-9.
3. Chittick GE, Zong J, Begley JA, Alianti JR, Sorbel JJ, Blum MR. Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination. Int J Clin Pharmacol Ther 2008; 46: 627-36.
4. Zong J, Chittick GE, Wang LH, Hui J, Begley JA, Blum MR. Pharmacokinetic evaluation of emtricitabine in combination with other nucleoside antivirals in healthy volunteers. J Clin Pharmacol 2007; 47: 877-89.
5. Gilead Sciences. Emtriva® prescribing information. 2012. Available at http://www.gilead.com/pdf/emtriva-pi.pdf (last accessed 4 April 2014).
6. Wang LH, Begley J, St Claire RL III, Harris J, Wakeford C, Rousseau FS. Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. AIDS Res Hum Retroviruses 2004; 20: 1173-82.
7. Valade E, Tréluyer J-M, Bouazza N, Ghosn J, Foissac F, Benaboud S, Fauchet F, Viard J-P, Urien S, Hirt D. Population pharmacokinetics of emtricitabine in HIV-1-infected adult patients. Antimicrob Agents Chemother 2014; 58: 2256-61.
8. World Health Organization. Use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2012. Available at http://whqlibdoc.who.int/hq/2012/WHO-HIV-2012.6-eng.pdf?ua=1 (last accessed 4 April 2014).
9. World Health Organization. Rapid advice: use of antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2010. Available at http://whqlibdoc.who.int/publications/2009/9789241598934-eng.pdf?ua=1 (last accessed 4 April 2014).
10. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet 2005; 44: 989-1008.
11. Hirt D, Urien S, Rey E, Arrivé E, Ekouévi DK, Coffié P, Leang SK, Lalsab S, Avit D, Nerrienet E, McIntyre J, Blanche S, Dabis F, Tréluyer J-M. Population pharmacokinetics of emtricitabine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Antimicrob Agents Chemother 2009; 53: 1067-73.
12. Flynn PM, Mirochnick M, Shapiro DE, Bardeguez A, Rodman J, Robbins B, Huang S, Fiscus SA, Van Rompay KKA, Rooney JF, Kearney B, Mofenson LM, Watts DH, Jean-Philippe P, Heckman B, Thorpe E Jr., Cotter A, Purswani M; PACTG 394 Study Team. Pharmacokinetics and safety of single-dose tenofovir disoproxil fumarate and emtricitabine in HIV-1-infected pregnant women and their infants. Antimicrob Agents Chemother 2011; 55: 5914-22.
13. Colbers APH, Hawkins DA, Gingelmaier A, Kabeya K, Rockstroh JK, Wyen C, Weizsäcker K, Sadiq ST, Ivanovic J, Giaquinto C, Taylor GP, Moltó J, Burger DM, PANNA network. The pharmacokinetics, safety and efficacy of tenofovir and emtricitabine in HIV-1-infected pregnant women. AIDS Lond Engl 2013; 27: 739-48.
14. Stek AM, Best BM, Luo W, Capparelli E, Burchett S, Hu C, Li H, Read JS, Jennings A, Barr E, Smith E, Rossi SS, Mirochnick M. Effect of pregnancy on emtricitabine pharmacokinetics. HIV Med 2012; 13: 226-35.
15. Hirnschall G, Harries AD, Easterbrook PJ, Doherty MC, Ball A. The next generation of the World Health Organization's global antiretroviral guidance. J Int AIDS Soc. 2013; 16: 18757.
16. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. 2013. Available at http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727-eng.pdf?ua=1 (last accessed 4 April 2014).
17. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16: 31-41.
18. Le Saux T, Chhun S, Rey E, Launay O, Weiss L, Viard J-P, Pons G, Jullien V. Quantification of seven nucleoside/nucleotide reverse transcriptase inhibitors in human plasma by high-performance liquid chromatography with tandem mass-spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 865: 81-90.
19. Kuhn E, Lavielle M. Maximum likelihood estimation in nonlinear mixed effects models. Comput Stat Data Anal 2005; 49: 1020-38.
20. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed 2008; 90: 154-66.
21. Beal SL. Ways to fit a PK model with some data below the quantification limit. J Pharmacokinet Pharmacodyn 2001; 28: 481-504.
22. Schinazi RF. Assessment of the relative potency of emtricitabine and lamivudine. Letter to the editor. J Acquir Immune Defic Syndr 2003; 34: 243-5.
23. Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 1981; 88: 1-9.
24. Davison JM, Dunlop W. Renal hemodynamics and tubular function normal human pregnancy. Kidney Int 1980; 18: 152-61.
25. Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43: 1071-87.
26. Davison JM. Kidney function in pregnant women. Am J Kidney Dis 1987; 9: 248-52.
27. Maynard SE, Thadhani R. Pregnancy and the kidney. J Am Soc Nephrol 2009; 20: 14-22.